Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.
|24/05/2011||22/07/2011||Reimbursement not recommended at the submitted price|
3rd October 2011
Following a price revision the NCPE now consider Oncotype DX a cost-effective therapy to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positve, early stage breast cancer in Ireland.
The HSE has approved reimbursement following confidential price negotiations.